Biophytis

Focus: Biophytis is a Paris-based biotech startup focused on developing therapies for aging-related diseases, with a lean team of 1-50 employees founded in 2018. The company operates in a specialized niche targeting sarcopenia and muscle wasting indications.

Infectious Diseases

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Employees

1-50

Open Jobs

About Biophytis

AI assessmentNot Hiring

No open roles listed right now. Follow Biophytis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

No Drug and no aspecific intervention

Sarcopenia

N/A

Clinical Trials (1)

NCT03021798An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over

N/A

Help build intelligence for Biophytis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape drug development in the high-growth aging disease space with a focused pipeline on sarcopenia and muscle wasting
Direct exposure to clinical development with 4 active trials across Phase 2 and Phase 2/3 stages, offering hands-on impact on program advancement
Small, lean team structure enables rapid decision-making and visibility across multiple therapeutic areas

Watch Out For

Pre-revenue stage with no disclosed funding, creating significant financial stability uncertainty and burn-rate risk
Currently zero open positions with no active hiring, suggesting limited growth trajectory or budget constraints

Generated by Claude from Biophytis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BIO101

Sarcopenia

PHASE_2

Clinical Trials (1)

NCT03452488A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

Phase 2

BIO101

Muscle Wasting

PHASE_2

Clinical Trials (1)

NCT07411378Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Phase 2

BIO101

Covid-19

PHASE_2_3

Clinical Trials (1)

NCT04472728Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

Phase 2/3